Scholars Central

Conference abstractPublished 8 Jun 2015

ImmunorexTM as vaccine approach by its ability to inhibit HIV-1 and co-infecting pathogens : The role of its Lipid fraction carrier

Authors: Donatien Mavoungou

University of Health Science, Gabon

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

ImmunorexTM as an antagonist of HIV-1 Tat, removes the overproduction of IL-10, contributing to the restoration of TH1 and TH2 balance and prevents cooperation between HIV-1 and co-infecting pathogens. Mass spectroscopy of ImmunorexTM revealed presence of DHEA, salicin, threonine ,fatty acids among others molecules, having antiviral, antibacterial, anti pyretic, anti inflammatory and anti cancer activities. Objective: analyse ImmunorexTM lipids fraction (LCF) as a putative source of antibiotics. LCF microbicidal activity was assessed by the sensitivity using the methods of Chapman and Sabourreau. Escherichia Coli (E.coli), Staphylococusareus, Pseudomonas and Klebsiella were isolated from the urine of HIV-1-infected patients diagnosed by western Blot technique. Various antibiotic disc (ABD) have been impregnated at 25°C with the LCF (Group 1), then dried and incubated with various germs isolated in parallel with native counterparts in Group 2. The diameters were measured (cm) to compare sensitivity between groups. LCF showed significant increase of respective antibiotics via diameter (cm) : 16→28; 10→18 + Ac Claulamique for staphylococcus areus, LCF increased sensitivities of Amoxicilline, Cefotaxime (0→32), Netelmicine ( 20→34); Rifampicine (13→22).cefotaxime (21→24); Aztreonam (41→48) and Amoxicilline Ac clavulamique ( 0→18) for E. coli while for Klebsiella, sensitivities to ABD was: Amoxiciline + Ac. clavulamique (20→28;24→30); Neteilmicine (20→24; 20→28); LCF showedwhile for Pseudomonas, negligible sensitivities to ABD. ImmunorexTM revealed potential microbicide activity that may contribute to block HIV-1 infection and the cooperation with co-infecting pathogens, protecting the unavoidable TH1 and TH2 balance in a drug and vaccine approach against HIV-1, including Tat Oyi vaccine as suggested by Biosantech, France.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectInfectious Diseases
  • SubjectImmunology & Microbiology
  • SubjectMicrobiology
  • BylineArticles whose byline prints “Donatien Mavoungou”